Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy.

Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy. Minerva Urol Nefrol. 2018 Jul 23;: Authors: Ong WM, Zargar-Shoshtari K, Siva S, Zargar H Abstract Prostate-specific membrane antigen (PSMA) is a receptor highly expressed on the membranes of prostate cancer cells and provides a new opportunity for imaging and targeted therapy in metastatic prostate cancer. The use of radio-labelled peptides with high affinity for PSMA-receptor allows for localisation of oligo-metastasis to guide salvage lymph node dissection, and effective delivery of radionuclide therapy to prostate cancer cells. The favourable properties of Lutetium 177 (Lu) labelled PSMA peptides has put it at the forefront of targeted radio-ligand therapy in patients with metastatic prostate cancer without bone marrow involvement, and the preliminary studies have demonstrated satisfactory oncological and clinical response. This review discusses the current statistics of PSMA-guided salvage lymph node dissection, and outcomes and safety profile of radio-ligand therapy with a focus on 177Lu. PMID: 30037209 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research